The ruling party released a list of drugs with their old and current prices to buttress its claim that the prices remain unchanged. The list also carried the price which the media reported quoting the Congress leaders.
"The number of drugs whose prices are kept under control was 440 before BJP came to power and now their count is 489.
The statement of Rahul Gandhi is "factually incorrect, insensitive and immature. We strongly condemn it and see it as a false propaganda during election emerging out of the frustration of their certain defeat," he said.
Taking a dig at Gandhi, he said they never expected "much maturity and wisdom" from him "but he should do a little more homework before making such accusations".
Trivedi said, "He (Rahul) has just failed miserably in Lok Sabha polls. He is somebody who is a prime ministerial candidate since birth but did not speak much for 10 years in Lok Sabha. Being a senior member of the country's oldest party, he should practice some caution."
Accusing the Modi government of working for "big businessmen," Gandhi had alleged yesterday that it lifted control on drug prices at the behest of some US companies which has led to cancer medicines costing over Rs 1 lakh instead of Rs 8000 earlier.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
